Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029542 · ClinicalTrials.gov registry record
Home Reported Outcomes in C3G Study
A clinical trial of C3 Glomerulopathy, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07029542 is a study of C3 Glomerulopathy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 100 participants, below the 113-participant average among 3 other C3 Glomerulopathy trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07029542, a study of C3 Glomerulopathy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures (collected at baseline and monthly), the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL as reported by C3G patients and caregivers, including those taking iptacopan
Conditions Studied
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029542
The ClinicalTrials.gov registry entry for NCT07029542 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 3 other C3 Glomerulopathy trials with a reported enrollment target (12% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with C3 Glomerulopathy appearing as the primary indexed condition, and to 0 interventions.
NCT07029542 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07029542 about?
NCT07029542 is a clinical study titled "Home Reported Outcomes in C3G Study". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treat...
What is the current status of trial NCT07029542?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-07. Estimated completion is 2026-04-30.
What conditions does trial NCT07029542 study?
This clinical trial studies the following conditions: C3 Glomerulopathy.
Who is sponsoring clinical trial NCT07029542?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029542 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for C3 Glomerulopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
RECRUITING · Phase 3
-
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
ACTIVE NOT RECRUITING · Phase 3
-
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.